Related Experiment Video
Updated: Nov 29, 2025
Microfluidic Device for Recreating a Tumor Microenvironment in Vitro
Published on: November 20, 2011
Application of an open-chamber multi-channel microfluidic device to test chemotherapy drugs
Hui-Sung Moon1, Chang Eun Yoo2, Sangmin Kim3
1Samsung Genome Institute, Samsung Medical Center, Seoul, 06351, South Korea. moonhs82@gmail.com.
Abstract:
The use of precision medicine for chemotherapy requires the individualization of the therapeutic regimen for each patient. This approach improves treatment efficacy and reduces the probability of administering ineffective drugs. To ensure accurate decision-making in a timely manner, anticancer drug efficacy tests must be performed within a short timeframe using a small number of cancer cells. These requirements can be satisfied via microfluidics-based drug screening platforms, which are composed of complex fluidic channels and closed systems. Owing to their complexity, skilled manipulation is required. In this study, we developed a microfluidic platform, to accurately perform multiple drug efficacy tests using a small number of cells, which can be conducted via simple manipulation. As it is a small, open-chamber system, a minimal number of cells could be loaded through simple pipetting. Furthermore, the extracellular matrix gel inside the chamber provides an in vivo-like environment that enables the localized delivery of the drugs to spontaneously diffuse from the channels underneath the chamber without a pump, thereby efficiently and robustly testing the efficacy and resistance of multiple drugs. We demonstrated that this platform enabled the rapid and facile testing of multiple drugs using a small number of cells (~ 10,000) over a short period of time (~ 2 days). These results provide the possibility of using this powerful platform for selecting therapeutic medication, developing new drugs, and delivering personalized medicine to patients.
Insights
This study introduces a microfluidic platform for rapid anticancer drug screening using minimal cancer cells. The system simplifies testing, enabling personalized medicine decisions within two days.
Area of Science:
- Oncology
- Biomedical Engineering
- Microfluidics
Background:
- Precision medicine necessitates individualized chemotherapy regimens for improved efficacy and reduced ineffective drug administration.
- Current anticancer drug efficacy testing requires short timeframes and minimal cancer cells for timely clinical decisions.
- Existing microfluidics-based platforms, while effective, often demand complex manipulation due to intricate designs.
Purpose of the Study:
- To develop a user-friendly microfluidic platform for rapid and accurate anticancer drug efficacy testing.
- To enable multiple drug efficacy tests using a small number of cancer cells with simple manipulation.
- To create an in vivo-like environment for robust drug screening.
Main Methods:
- Development of a small, open-chamber microfluidic system facilitating easy cell loading via pipetting.
- Incorporation of extracellular matrix gel within the chamber to mimic in vivo conditions.
- Utilizing spontaneous drug diffusion from underlying channels for localized drug delivery without pumps.
Main Results:
- The platform successfully performed multiple drug efficacy tests using approximately 10,000 cancer cells.
- Testing was completed rapidly, within a timeframe of approximately 2 days.
- The system demonstrated efficient and robust testing of drug efficacy and resistance.
Conclusions:
- The developed microfluidic platform offers a rapid, facile, and cell-sparing method for anticancer drug screening.
- This technology holds significant potential for guiding therapeutic medication selection in personalized medicine.
- The platform can aid in the development of novel anticancer drugs and advance patient-specific treatment strategies.
More Related Videos
07:03Author Spotlight: Integrating Computational and Experimental Approaches in Precision Oncology
Published on: December 1, 2023
10:24Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
Published on: September 19, 2019